
Keywords: کارسینوما; kidney; carcinoma; renal cell; sunitinib; drug-related side effects and adverse reactions; drug administration scheduleAE, adverse event; AS, alternative schedule; LDH, lactate dehydrogenase; mRCC, metastatic renal cell cancer; OS, overall survival; PFS,